Survival after recurrence of Ewing's sarcoma family of tumors

Journal of Clinical Oncology

Volumn 23, Issue 19, 2005, Pages 4354-4362

  Barker, Lisa M ^a   Pendergrass, Thomas W ^a   Sanders, Jean E ^a   Hawkins, Douglas S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; NAVELBINE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PRIORITY JOURNAL; TREATMENT RESPONSE; BONE TUMOR; INFANT; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; SURVIVAL RATE;

EID: 22344432762     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.105     Document Type: Article

References (41)

1. Grier HE: The Ewing family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44:991-1004, 1997
2. Gurney JG, Swensen AR, Bulterys M: Malignant bone tumors, cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, in Ries LAG, Smith MA, Gurney JG, et al (eds): National Cancer Institute, SEER Program. Bethesda, MD, NIH publication 99-4649, 1999, pp 99-110
3. Grier H, Krailo M, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003
4. Nesbit ME, Gehan EA, Burgert EO, et al: Multimodal therapy for the management of primary, non-metastatic Ewing's sarcoma of bone: A long term follow-up study of the first intergroup study. J Clin Oncol 8:1664-1674, 1990
5. Burgert EO, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of non-pelvic, localized Ewing's Sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
6. Cotterill SJ, Ahrens S, Paulussen M, et al: Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18:3108-3114, 2000
7. Paulussen M, Ahrens S, Craft AW, et al: Ewing's tumours with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 16:3044-3052, 1998
8. Cangir A, Vietti TJ, Gehan EA, et al: Ewing's sarcoma metastatic at diagnosis: Results and comparisons of two Intergroup Ewing's Sarcoma Studies. Cancer 66:887-893, 1990
9. Shankar AG, Pinkerton CR, Atra A, et al: Local therapy and other factors influencing site of relapse in patients with localized Ewing's sarcoma. Eur J Cancer 35:1698-1704, 1999
10. Ahrens S, Hoffman C, Jabar S, et al: Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience. Med Pediatr Oncol 32:186-195, 1999
11. Horowitz ME, Kinsella TJ, Wexler LH, et al: Total body irradiation and autologous bone marrow transplant in the treatment of high risk Ewing's sarcoma, rhabdomyosarcoma. J Clin Oncol 11:1911-1918, 1993
12. Burdach S, Jurgens H, Peters C, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 11:1482-1488, 1993
13. Hayes FA, Thompson El, Kumar M, et al: Long-term survival in patients with Ewing's sarcoma relapsing after completing therapy. Med Pediatr Oncol 15:254-256, 1987
14. Shankar AG, Ashley S, Craft AW, et al: Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 40:141-147, 2003
15. Rodriguez-Galindo C, Billups CA, Kun LE, et al: Survival after recurrence of Ewing tumors: The St. Jude Children's Research Hospital experience, 1979-1999. Cancer 94:561-569, 2002
16. Bacci G, Ferrari S, Longhi A, et al: Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14:1654-1659, 2003
17. Saylor RL, Stine KC, Sullivan J, et al: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-3469, 2001
18. Miser JS, Kinsella TJ, Triche TJ, et al: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987
19. Cairo MS, Shen V, Krailo MD, et al: Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: A Children's Cancer Group report. J Pediatr Hematol Oncol 23:30-38, 2001
20. Hawkins D, Barnett T, Bensinger W, et al: Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors. Med Pediatr Oncol 34:328-337, 2000
21. Burdach S, Meyer-Bahlburg A, Laws HJ, et al: High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: Results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21:3072-3078, 2003
22. Ladenstein R, Lasset C, Pinkerton R, et al: Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: A report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 15:697-705, 1995
23. Womer RB, Daller RT, Fenton JG, et al: Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 36:87-94, 2000
24. Felgenhauer J, Hawkins D, Pendergrass T, et al: Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. Med Pediatr Oncol 34:29-38, 2000
25. Hawkins D, Felgenhauer J, Park J, et al: Peripheral blood progenitor cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer 95:1354-1365, 2002
26. Nitschke R, Parkhurst J, Sullivan J, et al: Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318, 1998
27. Blaney SM, Seibel NL, O'Brien M, et al: Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 15:1538-1543, 1997
28. Casanova M, Ferrari A, Spreafico F, et al: Vinorelbine in previously treated advanced childhood sarcoma: Evidence of activity in rhabdomyosarcoma. Cancer 94:3263-3268, 2002
29. Crist W, Gehan EA, Ragab AH, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630, 1995
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Analysis and examples. Br J Cancer 35:1-39, 1977
32. Kaleish JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
33. Burdach S: Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplants. Pediatr Transplant 8:67-82, 2004 (suppl 5)
34. Perentesis JP, Katsanis E, DeFor TE, et al: Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 24:609-615, 1999
35. Davies SM, Defor TM, Weigel BJ, et al: High dose busulfan-based chemotherapy with autologous stem cell transplantation (ASCT) for high risk Ewing's sarcoma family tumors. Proc Am Soc Clin Oncol 20:364a, 2001 (abstr)
36. Burdach S, Jürgens H: High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 41:169-189, 2002
37. Meyers PA, Krailo MD, Ladanyi M, et al: High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19:2812-2820, 2001
38. Kushner BH, Meyers PA: How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 19:870-880, 2001
39. Paulussen M, Ahrens S, Burdach S, et al: Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies-European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 9:275-281, 1998
40. Leu KM, Ostruszka LJ, Shewach D, et al: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706-1712, 2004
41. Batra S, Maurer BJ, Reynolds CP: Fenretinide cytotoxicity in Ewing's sarcoma (ES) and primitive neuroectodermal (PNET) cell lines is blunted by hypoxia but synergistically enhanced by safingol. Med Pediatr Oncol 37:178, 2001 (abstr)